Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma.
Hsieh
Ching-Yun
CY
Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Huang
Hsin-Hui
HH
Lin
Chen-Yuan
CY
Chung
Lo Woei
LW
Liao
Yu-Mine
YM
Bai
Li-Yuan
LY
Chiu
Chang-Fang
CF
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016174:Hepacivirus / Q000502:physiology*; D006526:Hepatitis C / Q000821:virology*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D049268:Positron-Emission Tomography; D012367:RNA, Viral / Q000032:analysis; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D014775:Virus Activation / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D012367:RNA, Viral; D000069283:Rituximab